NON-HODGKIN LYMPHOMA

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV can cause serious illness in people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA to help the body build immuni…

This early-phase study tests a new drug called GNC-038, a quad-specific antibody designed to attack cancer cells in people with relapsed or refractory non-Hodgkin's lymphoma or acute lymphoblastic leukemia. The main goals are to check the drug's safety, find the right dose, and s…

This study tests a new drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma (a blood cancer). The goal is to see if the drug can shrink tumors or keep the cancer from growing. About 320 adults with measurable tumors and …

This early-phase study is testing an experimental drug called GNC-038 in people with certain lymphomas (NK/T-cell, AITL, and other non-Hodgkin lymphomas) that have returned or not responded to standard therapy. The main goals are to check safety, find the best dose, and see if th…

This early-stage study tests a new treatment called SC291 for people with certain types of blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. SC291 is a type of CAR T cell therapy made from donor cel…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vo…

This study tests a drug called acalabrutinib, alone or with other medicines, in people with a type of blood cancer called B-cell non-Hodgkin lymphoma. The goal is to see if the treatment is safe and helps shrink or control the cancer. About 113 adults with lymphoma that came back…

This early-phase study tests whether adding the drug duvelisib after CAR T-cell therapy can help the immune cells stay active longer and reduce side effects like cytokine release syndrome. About 42 adults with non-Hodgkin lymphoma or acute lymphocytic leukemia will take part. The…

This study tests a combination of the immunotherapy drug pembrolizumab and low-dose radiation in people with non-Hodgkin lymphoma that has come back or not responded to treatment. Participants receive radiation to one or more tumor sites and then continue pembrolizumab until the …

This early-phase study tests whether giving targeted radiation before standard CAR T-cell therapy is safe and practical for people with relapsed or refractory B-cell lymphoma. About 20 participants will receive radiation to all active disease sites before their CAR T infusion. Th…

This study tests an experimental drug called WTX-330 in about 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The main goals are to find safe dose levels and see if the drug can shrink tumors. Researchers will also mea…

This early-stage study tests a new, fast-made CAR-T cell therapy (UF-KURE19) in 21 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check the therapy's safety and find the right dose. Researchers also want to see if it …

This early-phase study tests an experimental drug called DS-3201b in adults with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how well the drug works. About 100 participants will take p…

This early-phase study tests whether adding specially treated immune cells (called veto cells) from a donor can help stem cell transplants work better in people with blood cancers like leukemia or lymphoma. The goal is to help the donor cells grow without causing severe graft-ver…

This early-phase study tests an experimental oral drug called APG-2575 in adults with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take t…

This study planned to test a combination of two drugs, golcadomide and nivolumab, in adults with non-Hodgkin lymphoma that continued to grow or came back after CAR-T cell therapy. The goal was to find the safest dose and see if the combo could shrink tumors. However, the trial wa…

This early-phase trial tests whether giving healthy donor NK cells along with two drugs (vactosertib and IL-2) is safe and helps the cells survive longer in people with advanced colorectal, stomach/esophageal, or blood cancers. About 12 participants will receive the combination t…

This study tests whether a combination of two drugs (mosunetuzumab and polatuzumab vedotin) works better than standard chemotherapy for people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. About 208 adults with certain types of lymphoma will…

This study tests whether specially trained immune cells from healthy donors can safely fight cancers and diseases caused by the Epstein-Barr virus (EBV). Participants have EBV-positive lymphoma, nasopharyngeal carcinoma, or other EBV-related conditions that returned or didn't res…

This early-phase study tests a personalized treatment where a patient's own immune cells (T cells) are collected, modified in a lab to recognize and attack cancer cells, and then infused back. It is for adults with non-Hodgkin lymphoma that has returned or not responded to at lea…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or sever…

This early-phase trial tests a new treatment called huCART19-IL18 for people with certain blood cancers (leukemia and lymphoma) that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to better find and attack cancer cel…

This study offers ongoing CC-122 treatment to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor safety and side effects over the long term. It is not a cure, but aims t…

This study looks at whether a special PET scan using a natural substance called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors, tell how aggressive they are, and tell leftove…

This early-phase trial tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can help protect the transplant recipient from CMV infection. About 34 people with blood cancers receiving a donor stem cell transplant will have their donors vaccinated before donatio…

This study tests whether adding acupuncture to standard pain care can lower the use of opioid painkillers in people with multiple myeloma, Hodgkin disease, or non-Hodgkin lymphoma who are about to receive high-dose chemotherapy. About 299 adults will be randomly assigned to get e…

This study tests if shorter courses of radiation are safe for people with lymphoma that has returned or not responded to treatment. About 30 participants will receive different shortened radiation schedules to find the safest dose. The goal is to reduce treatment time while contr…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…

This study follows 500 adults aged 18 to 65 who finished their first chemotherapy treatment for certain cancers and are in remission. Over 5 years, researchers will check for 19 possible late side effects, like heart or lung problems, and offer follow-up care. The goal is to bett…

This study follows about 150 people who have already received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to track any long-term side effects for up to 15 years after treatment. No new treatments are given—just regular check-ups to monitor safety…

This study looks at how blood cancers and stem cell transplants impact muscle function in 144 patients. Researchers want to see if muscle problems can help predict complications like infections, hospital stays, or survival. The goal is to better understand recovery and guide futu…